I. BACTERIAL PATHOGENESIS

B. VIRULENCE FACTORS THAT PROMOTE BACTERIAL COLONIZATION OF THE HOST

5. The ability to resist innate immune defenses such as phagocytosis, complement, and antibacterial peptides

b. The ability to resist phagocytic engulfment and antibacterial peptides

Fundamental Statements for this Learning Object:

1. Capsules can resist unenhanced attachment by by preventing pathogen-associated molecular patterns or from binding to endocytic pattern-recognition receptors on the surface of the phagocytes.
2. The capsules of some bacteria interfere with the body's complement pathway defenses.
3. The body's immune defenses can eventually get around the capsule by producing opsonizing antibodies (IgG) against the capsule that stick the capsule to the phagocyte. This is the principle behind some vaccines.
4. Biofilms enable bacteria to: resist attack by antibiotics; trap nutrients for bacterial growth and remain in a favorable niche; adhere to environmental surfaces and resist flushing; live in close association and communicate with other bacteria in the biofilm; and resist phagocytosis and attack by the body's complement pathways.
5. Certain bacteria can resist antibacterial peptides.

 

LEARNING OBJECTIVES FOR THIS SECTION


 

In this section on Bacterial Pathogenesis we are looking at virulence factors that promote bacterial colonization of the host. The following are virulence factors that promote bacterial colonization of the host .

1. The ability to use motility and other means to contact host cells and disseminate within a host.
2. The ability to adhere to host cells and resist physical removal.
3. The ability to invade host cells.
4. The ability to compete for iron and other nutrients.
5. The ability to resist innate immune defenses such as phagocytosis and complement.
6. The ability to evade adaptive immune defenses.

Some bacteria are able to resist innate immune defenses such as phagocytosis and the body's complement pathways. We will break this down into two categories:

1. The ability to resist phagocytic engulfment (attachment and ingestion)

2. The ability to resist phagocytic destruction and complement serum lysis

We will now look virulence factors (def) that enable bacteria to resist phagocytic engulfment (attachment and ingestion) and antibacterial peptides.


5. The Ability to Resist Innate Immune Defenses such as Phagocytosis, Complement, and Antibacterial peptides

b. The Ability to Resist Phagocytic Engulfment (Attachment and Ingestion) and Antibacterial Peptides

As we learned in Unit 1, capsules enable many organisms to resist phagocytic engulfment. For example, Streptococcus pneumoniae (inf) is able to initially evade phagocytosis and cause infections such as pneumococcal pneumonia, sinusitis, otitis media, and meningitis because of its capsule. Encapsulated strains of Haemophilus influenzae type b (inf) can causes severe respiratory infections, septicemia, epiglottitis (def), and meningitis in children. (Other non-encapsulated strains of H. influenzae usually cause mild respiratory infections such as sinusitis and otitis media.) Other encapsulated bacteria include Neisseria meningitidis (inf), Bacillus anthracis (inf) , and Bordetella pertussis (inf).

 


Highlighted Bacterium:
Haemophilus influenzae

Click on this link, read the description of Haemophilus influenzae, and be able to match the bacterium with its description on an exam.

 

 

You Tube Movie illustrating bacterial phagocytosis by a neutrophil.
Movie of an encapsulated bacterium resisting engulfment by a neutrophil.

 

1. Capsules can resist unenhanced attachment by preventing pathogen-associated molecular patterns or PAMPs (def) - components of common molecules such as peptidoglycan, teichoic acids, lipopolysaccharide, mannans, and glucans common in microbial cell walls but not found on human cells - from binding to endocytic pattern-recognition receptors (def) on the surface of the phagocytes (see Fig. 1).

 

2. The capsules of some bacteria interfere with the body's complement pathways (def). Capsules can interfere with the complement pathways in a number of ways:

a. Some capsules prevent the formation of C3 convertase, an early enzyme in the complement pathways. Without this enzyme, the opsonins (def) C3b and C4b involved in enhanced attachment, as well as the other beneficial complement proteins like C5a, are not produced.

    b. Some capsules are rich in sialic acid, a common component of host cell glycoprotein. Sialic acid has an affinity for serum protein H, a complement regulatory protein that leads to the degradation of the opsonin C3b (def) and the formation of C3 convertase. (Our body uses serum protein H to degrade any C3b that binds to host cell glycoproteins so that we don't stick our own phagocytes to our own cells with C3b.) Some Neisseria meningitidis (inf) strains synthesize their own sialic acid capsule. While Neisseria gonorrhoeae (inf) and Hemophilus influenzae type b (inf) do not have a sialic acid capsule, they are able to scavenge sialic acid from host cells and enzymatically transfer it to their surface where it subsequently binds protein H.

    c. Some capsules simply cover the C3b (def) that does bind to the bacterial surface and prevent the C3b receptor on phagocytes from making contact with the C3b (see Fig. 2). This is seen with the capsule of Streptococcus pneumoniae (inf).

     

by Gary E. Kaiser, Ph.D.
Professor of Microbiology, The Community College of Baltimore County, Catonsville Campus
This work is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work The Grapes of Staph at https://cwoer.ccbcmd.edu/science/microbiology/index_gos.html.

Creative Commons License

Last updated: August, 2019
Please send comments and inquiries to Dr. Gary Kaiser


    d. Staphylococcus aureus (inf) produces a protein called Staphylococcal complement inhibitor that binds and inhibits the C3 convertase enzyme needed for all three complement pathways.

The body's immune defenses, however, can eventually get around the capsule by producing opsonizing antibodies (IgG) against the capsule. The antibody then sticks the capsule to the phagocyte. In vaccines against pneumococccal pneumonia (inf) and Haemophilus influenzae type b (inf), it is capsular polysaccharide that is given as the antigen (def) in order to stimulate the body to make opsonizing antibodies against the encapsulated bacterium.

 

by Gary E. Kaiser, Ph.D.
Professor of Microbiology, The Community College of Baltimore County, Catonsville Campus
This work is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work The Grapes of Staph at https://cwoer.ccbcmd.edu/science/microbiology/index_gos.html.

Creative Commons License

Last updated: August, 2019
Please send comments and inquiries to Dr. Gary Kaiser

 

3. Biofilms

Many pathogenic bacteria, as well as normal flora, form complex bacterial communities as biofilms. Bacteria in biofilms are often able to communicate with one another by a process called quorum sensing and are able to interact with and adapt to their environment as a population of bacteria rather than as individual bacteria. By living as a community of bacteria as a biofilm, these bacteria are better able to:

Biofilms are, therefore, functional, interacting, and growing bacterial communities. Biofilms even contain their own water channels for delivering water and nutrients throughout the biofilm community.

For example, Pseudomonas aeruginosa (inf) produces a glycocalyx composed of alginate. This enables strains producing the glycocalyx to block neutrophil chemotaxis, scavenge the hypochlorite molecules produced by neutrophils to kill bacteria, decrease phagocytosis, and inhibit activation of the complement pathways.

 

4. Certain bacteria can resist phagocytic engulfment and complement (def) using mechanisms not involving capsules.

a. The M-protein of Streptococcus pyogenes (inf) allows these bacteria to be more resistant to phagocytic engulfment. The M-protein of S. pyogenes binds factor H, a complement regulatory protein that leads to the degradation of the opsonin C3b (def) and the formation of C3 convertase. (Our body uses serum protein H to degrade any C3b that binds to host cell glycoproteins so that we don't stick our own phagocytes to our own cells with C3b.) S. pyogenes also produces a protease that cleaves the complement protein C5a.

by Gary E. Kaiser, Ph.D.
Professor of Microbiology, The Community College of Baltimore County, Catonsville Campus
This work is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work The Grapes of Staph at https://cwoer.ccbcmd.edu/science/microbiology/index_gos.html.

Creative Commons License

Last updated: August, 2019
Please send comments and inquiries to Dr. Gary Kaiser

 

 

 

5. Certain bacteria can resist antibacterial peptides

Human defensins (def) are short cationic peptides 29-34 amino acids long that are directly toxic by forming pores in the cytoplasmic membrane of a variety of microorganisms causing leakage of cellular needs. They also activate cells for an inflammatory response. Defensins are produced by leukocytes, epithelial cells, and other cells. They are also found in blood plasma and mucus. Cathelicidins (def) are proteins produced by skin and mucosal epithelial cells. The two peptides produced upon cleavage of the cathelicidin are directly toxic to a variety of microorganisms. One pepitide also can bind to and neutralize LPS from Gram-negative cell walls to reduce inflammation.

a. Capsules help prevent antibacterial peptides from reaching the cytoplasmic membrane of some bacteria.

 

 

Medscape article on infections associated with organisms mentioned in this Learning Object. Registration to access this website is free.

 

 

Gary E. Kaiser, Ph.D.
Professor of Microbiology
The Community College of Baltimore County, Catonsville Campus
This work is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work The Grapes of Staph at https://cwoer.ccbcmd.edu/science/microbiology/index_gos.html.

Creative Commons License

Last updated: Feb., 2021
Please send comments and inquiries to Dr. Gary Kaiser